#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

# SCHEDULE 13D

## Under the Securities Exchange Act of 1934

(Amendment No.)\*

DBV Technologies S.A. (Name of Issuer)

## Ordinary Shares, nominal value $\in 0.10$ per share

(Title of Class of Securities)

23306J101

(CUSIP number)

Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21<sup>st</sup> Floor New York, NY 10065 (212) 339-5690

(Name, address and telephone number of person authorized to receive notices and communications)

Not Applicable

(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(g), check the following box.

(Continued on the following pages)

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 23306J101

Page <u>2</u> of <u>11</u> Pages

-	1			
1.	NAMES OF REPORTING PERSONS			
	Baker Bros. Advisors LP			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*       (a) □         (b) □			
3.	SEC USE ONLY			
4.	SOURCE OF FUNDS* OO			
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
	NUMBER OF	7.	SOLE VOTING POWER 3,600,318	
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER: 0	
			SOLE DISPOSITIVE POWER: 3,600,318	
		10.	SHARED DISPOSITIVE POWER: 0	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 3,600,318			
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.9%(1)			
14.	TYPE OF REPORTING PERSON (See Instructions) IA, PN			
(1)			es outstanding as of August 31, 2015, according to information received from the Issuer on Sentem	1 15 00

## CUSIP No 23306J101

Page <u>3 of 11</u> Pages

1.	NAMES OF REPORTING PERSONS			
	Baker Bros. Advisors	(GP) LLC		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) $\Box$ (b) $\Box$			
3.	SEC USE ONLY			
4.	SOURCE OF FUNDS* OO			
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
	NUMBER OF	7.	SOLE VOTING POWER 3,600,318	
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER: 0	
			SOLE DISPOSITIVE POWER: 3,600,318	
			SHARED DISPOSITIVE POWER: 0	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 3,600,318			
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.9%(1)			
14.	TYPE OF REPORTING PERSON (See Instructions) HC, OO			

## CUSIP No. 23306J101

Page <u>4</u> of <u>11</u> Pages

	1			
1.	NAMES OF REPORTING PERSONS			
	Julian C. Baker			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b) (b)			
3.	SEC USE ONLY			
4.	SOURCE OF FUNDS* OO			
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States			
	NUMBER OF	7.	SOLE VOTING POWER: 3,600,318	
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER: 0	
			SOLE DISPOSITIVE POWER: 3,600,318	
			SHARED DISPOSITIVE POWER: 0	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 3,600,318			
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.9%(1)			
14.	TYPE OF REPORTING PERSON (See Instructions) IN, HC			

## CUSIP No 23306J101

Page <u>5</u> of <u>11</u> Pages

1.	NAMES OF REPORTING PERSONS			
	Felix J. Baker			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) $\Box$ (b) $\Box$			
3.	SEC USE ONLY			
4.	SOURCE OF FUNDS (See Instructions) OO			
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States			
	NUMBER OF	7.	SOLE VOTING POWER: 3,600,318	
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER: 0	
			SOLE DISPOSITIVE POWER: 3,600,318	
			SHARED DISPOSITIVE POWER: 0	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 3,600,318			
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 14.9%(1)			
14.	TYPE OF REPORTING PERSON (See Instructions) IN, HC			

#### Schedule 13D

## ITEM 1. Security and Issuer

The class of equity security to which this statement on Schedule 13D relates is the ordinary shares, nominal value  $\notin 0.10$  per share (the "Ordinary Shares") of DBV Technologies, S.A., a Société Anonyome, incorporated under the laws of France (the "Issuer"). The address of the principal executive offices of the Issuer is Green Square-Bâtiment D 80/84 rue des Meuniers 92220 Bagneux France. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

#### ITEM 2. Identity and Background.

(a) The Reporting Persons are:

- 1. Baker Bros. Advisors LP (the "Adviser")
- 2. Baker Bros. Advisors (GP) LLC (the "Adviser GP")
- 3. Felix J. Baker
- 4. Julian C. Baker

(b) The business address of each of the Reporting Persons is:
c/o Baker Bros. Advisors LP
667 Madison Avenue, 21<sup>st</sup> Floor
New York, NY 10065
(212) 339-5690

(c) The Adviser is an entity engaged in investment activities, and the Adviser GP is in the business of acting as its general partner and, through the Adviser, investment activities. The principal business of each of Julian C. Baker and Felix J. Baker is to serve as a managing member of the Adviser GP.

(d) and (e) During the past five years, none of the Reporting Persons nor any of the Funds (as defined below) has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The Adviser is a limited partnership organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

#### Item 3. Source and Amount of Funds or Other Consideration

The disclosure in Item 4 below is incorporated herein by reference.

#### Item 4. Purpose of the Transaction.

667, L.P. ("667"), and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") hold securities of the Issuer previously purchased in open market transactions directly with a broker dealer, underwritten public offerings, and in private transactions directly with the Issuer using working capital of the Funds. The aggregate purchase price of the 3,600,318 Ordinary Shares directly held by Funds was approximately \$181.4MM.

The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of Ordinary Shares or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors and management of the Issuer, the availability and nature of opportunities to dispose of shares of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and may make suggestions to the management of the Issuer regarding corporate financing and strategy, and may acquire or dispose of securities of the Issuer (by means of open market purchases, privately negotiated purchases, or otherwise).

Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

#### Item 5. Interest in Securities of the Issuer.

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. Set forth below is the aggregate number of Ordinary Shares of the Issuer directly held along with American Depositary Shares directly held by each of the Funds and the percentage of the Issuer's outstanding Ordinary Shares such holdings represent. Each American Depositary Share represents one-half of one Ordinary Shares of the Issuer. The information set forth below is based upon 24,103,749 Ordinary Shares outstanding as of August 31, 2015, according to information obtained from the Issuer on September 15, 2015. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

	Number of	
	Ordinary Shares	
	we own or have to	Percent of
	right to acquire	Class
Name	within 60 days	Outstanding
667, L.P.	302,269	1.3%
Baker Brothers Life Sciences, L.P.	3,298,049	13.6%
Total	3,600,318	14.9%

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities of the Issuer held by each of the Funds, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any such Reporting Persons actually exercises voting or dispositive power with respect to such securities.

Pursuant to management agreements, as amended, among the Adviser, the Funds, and their respective general partners, the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments.

(c) None of the Reporting Persons or their affiliates has effected any transactions in securities of the Issuer during the past 60 days.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

(e) Not applicable.

ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

None.

## Item 7. Material to Be Filed as Exhibits.

Exhibit	Description
99.1	Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 15, 2015

## BAKER BROS. ADVISORS LP

By: Baker Bros. Advisors (GP) LLC, its general partner

By: /s/ Scott L. Lessing Name: Scott L. Lessing Title: President

## BAKER BROS. ADVISORS (GP) LLC

By: /s/ Scott L. Lessing Name: Scott L. Lessing Title: President

/s/ Julian C. Baker

Julian C. Baker

/s/ Felix J. Baker Felix J. Baker

### JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the Ordinary Shares of DBV Technologies S.A.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

EXECUTED as of this 15th day of September 2015

## BAKER BROS. ADVISORS LP

By: Baker Bros. Advisors (GP) LLC, its general partner

By: /s/ Scott L. Lessing Name: Scott L. Lessing Title: President

## BAKER BROS. ADVISORS (GP) LLC

By: /s/ Scott L. Lessing Name: Scott L. Lessing Title: President

/s/ Julian C. Baker Julian C. Baker

/s/ Felix J. Baker Felix J. Baker